Showing results (3161-3170 of 10,080) with videos related to
Sort By:
Pageof 1,008
Current Pharmaceutical Design|November 25, 2005
Direct thrombin inhibitors for the prevention of venous thromboembolism after major orthopaedic surgeryGiancarlo Agnelli, Francesco Sonaglia, Cecilia BecattiniCurrent Pharmaceutical Design|November 25, 2005
Molecular mechanisms of and possible treatment strategies for idiopathic pulmonary fibrosisM Gharaee-Kermani, S H PhanCurrent Pharmaceutical Design|October 28, 2005
RNA interference-based gene silencing in mice: the development of a novel therapeutical strategyBirgit Spänkuch, Klaus StrebhardtCurrent Pharmaceutical Design|October 28, 2005
Pharmacological intervention of cyclooxygenase-2 and 5-lipoxygenase pathways. Impact on inflammation and cancerJ Clària, M RomanoCurrent Pharmaceutical Design|October 28, 2005
Large artery stiffness and antihypertensive agentsJacques Blacher, Athanase D Protogerou, Michel E SafarCurrent Pharmaceutical Design|October 27, 2005
Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapyAlessandro D Santin, Stefania Bellone, Juan J Roman, et al.Current Pharmaceutical Design|October 27, 2005
Direct evidence on the immune-mediated spontaneous regression of human cancer: an incentive for pharmaceutical companies to develop a novel anti-cancer vaccineF Saleh, W Renno, I Klepacek, et al.Current Pharmaceutical Design|October 27, 2005
Why drugs fail--a study on side effects in new chemical entitiesD Schuster, C Laggner, T LangerCurrent Pharmaceutical Design|November 14, 2009
Unraveling monoamine receptors involved in the action of typical and atypical antipsychotics on glutamatergic and serotonergic transmission in prefrontal cortexXavier López-Gil, Francesc Artigas, Albert AdellCurrent Pharmaceutical Design|November 14, 2009
Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysisGuochuan E Tsai, Pao-Yen LinPageof 1,008